Axsome Launches Phase III FORWARD Trial of AXS-14 for Fibromyalgia
As reported by Clinical Trials Arena, Axsome Therapeutics has begun dosing patients in its FORWARD Phase III clinical trial, a pivotal study designed to evaluate the investigational therapy AXS‑14 (esreboxetine)…